These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15080377)

  • 1. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial.
    Yui Y; Sumiyoshi T; Kodama K; Hirayama A; Nonogi H; Kanmatsuse K; Origasa H; Iimura O; Ishii M; Saruta T; Arakawa K; Hosoda S; Kawai C;
    Hypertens Res; 2004 Mar; 27(3):181-91. PubMed ID: 15080377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis.
    Yui Y; Sumiyoshi T; Kodama K; Hirayama A; Nonogi H; Kanmatsuse K; Origasa H; Iimura O; Ishii M; Saruta T; Arakawa K; Hosoda S; Kawai C
    Hypertens Res; 2004 Jul; 27(7):449-56. PubMed ID: 15302980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy).
    Yui Y; Shinoda E; Kodama K; Hirayama A; Nonogi H; Haze K; Sumiyoshi T; Hosoda S; Kawai C;
    J Hypertens; 2007 Oct; 25(10):2019-26. PubMed ID: 17885543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [JMIC-B study and its sub-analyses: effect of nifedipine in Japanese hypertensive patients with coronary artery disease].
    Yui Y
    Drugs; 2006; 66 Spec No 1():25-7. PubMed ID: 18200776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of captopril and nifedipine in black and white patients with hypertensive crisis.
    Damasceno A; Ferreira B; Patel S; Sevene E; Polónia J
    J Hum Hypertens; 1997 Aug; 11(8):471-6. PubMed ID: 9322826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse remodeling and improved function by antihypertensive treatment in hypertensive patients with coronary artery disease.
    Yui Y; Kodama K; Hirayama A; Nishio R; Iwanaga Y; Nonogi H; Haze K; Sumiyoshi T; Yui N; Hosoda S; Kawai C;
    J Hypertens; 2010 Jan; 28(1):178-85. PubMed ID: 19927011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease.
    Marin R; Ruilope LM; Aljama P; Aranda P; Segura J; Diez J;
    J Hypertens; 2001 Oct; 19(10):1871-6. PubMed ID: 11593109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Leenen FH; Nwachuku CE; Black HR; Cushman WC; Davis BR; Simpson LM; Alderman MH; Atlas SA; Basile JN; Cuyjet AB; Dart R; Felicetta JV; Grimm RH; Haywood LJ; Jafri SZ; Proschan MA; Thadani U; Whelton PK; Wright JT;
    Hypertension; 2006 Sep; 48(3):374-84. PubMed ID: 16864749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
    Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
    J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation.
    Grekas D; Dioudis C; Kalevrosoglou I; Papoulidou F; Goutsaridis N; Alivanis P; Tourkantonis A
    Clin Nephrol; 1995 Nov; 44(5):299-302. PubMed ID: 8605709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
    Saito I; Saruta T;
    Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study).
    Shinoda E; Yui Y; Kodama K; Hirayama A; Nonogi H; Haze K; Sumiyoshi T; Hosoda S; Kawai C;
    Hypertension; 2005 Jun; 45(6):1153-8. PubMed ID: 15851624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension.
    Persson B; Widgren BR; Fox A; Stimpel M
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):73-8. PubMed ID: 7564369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative assessment of a calcium antagonist with controlled release of nifedipine and enalapril in arterial hypertension in subjects older than 60 years].
    Oleĭnikov VE; Grishaeva EE; Borisova NA; Iastrebova EI; Fadeeva SS
    Kardiologiia; 2009; 49(5):34-9. PubMed ID: 19463133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effects of two modified release preparations of nifedipine-nifedipine retard 10 mg twice daily and nifedipine GITS 20 mg once daily--in the treatment of mild to moderate hypertension.
    Kirby BJ; Kitchin NR
    Int J Clin Pract; 1999; 53(5):339-43. PubMed ID: 10695096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina.
    Elliott HL; Meredith PA
    J Hum Hypertens; 2011 Jan; 25(1):63-70. PubMed ID: 20182454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.
    Schroeder EB; Chonchol M; Shetterly SM; Powers JD; Adams JL; Schmittdiel JA; Nichols GA; O'Connor PJ; Steiner JF
    Clin J Am Soc Nephrol; 2018 May; 13(5):727-734. PubMed ID: 29572286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of treatment effects with an angiotensin converting enzyme inhibitor--lisinopril and a calcium blocker--nifedipine retard on urinary albumin excretion in patients with non-complicated essential hypertension].
    Widecka K; Celibała R; Czekalski S
    Pol Arch Med Wewn; 1995 Feb; 93(2):135-42. PubMed ID: 7479231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.
    Messerli FH; Oparil S; Feng Z
    Am J Cardiol; 2000 Dec; 86(11):1182-7. PubMed ID: 11090788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
    Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
    Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.